Thu, Oct 7, 2021

09:00 – 11:05

ICRS – Session 20: Industry session

Chair: Ofra Benny, The Hebrew University of Jerusalem

Ayelet Ofarim
Chemical Abstracts Service, Arad Ophir Ltd., Ramat Hasharon, Israel
Controlled-release packaging– A case study in SciFinder discovery platform

Osnat Bohana-Kashtan1, Ira Gotliv1, Oded Pinkas1, Haim Tsubery1, Neta Chaim1, Noa Avni1, Hanna Eruhimovich1, Michal Wolk1, Tal Yoetz1, Marcelle Machluf1,2
1R&D, NanoGhost, Netanya, Israel, Israel
2Biotechnology and Food Engineering, Tehnion – Israel Institute of Technology, Haifa, Israel
NanoGhost – Harnessing the homing nature of stem cells in a drug targeting platform

Helen Domeshek
Drug Substance Development, Recipharm, Yavne, Israel
From drug candidate to proof of concept

Mor Goldfeder
., PEEL Therapeutics, Nesher, Israel

10:00- 10:30

Coffee Break

10:30 – 12:35

ICRS – Session 21: Clinical oncology & cancer targeted delivery

Chair: Dan Peer, Tel Aviv University

Dan Peer
Shmunis School of Biomedicine and Cancer Research, Tel Aviv University, Tel Aviv, Israel
RNA therapeutics: From gene silencing to gene editing

Ronit Satchi-Fainaro
Tel Aviv University, Tel Aviv, Israel
Dendritic cells-targeted nano-vaccines sensitize melanoma to immune checkpoint modulators

Alex Tendler, Alex Tendler, Lana Volokh, Kasuto Harel
Bio-Tech, Exoprother Medical, Yokneam, Haifa, Israel
P53 containing natural nanovesicles of xenogenic origin as highly effective oncology therapy demonstrated in syngeneic murine model.

Ofra Benny
Faculty of Medicine, School of Pharmacy, The Hebrew University for Jerusalem, Jerusalem, Israel
Biomechanical targeting as a novel approach for drug delivery in cancer

Yosi Shamay
Biomedical Engineering, Technion – Israel Institute of Technology, Haifa, Israel
Nanoinformatics for personalized cancer nanomedicine: From literature data mining to optimized molecular structures

12:35- 13:00

Light Lunch

13:00- 13:10